Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 13, 2013 - Issue 7
Submit an article Journal homepage
75
Views
1
CrossRef citations to date
0
Altmetric
Theme: Urological Cancer - Review

Accurate patient selection and multimodal treatment offer the best therapeutic option in high-risk prostate cancer

François Rozet Department of Urology, Institut Montsouris, 75014 Paris, France. [email protected]
,
François Audenet Department of Urology, Institut Montsouris, 75014 Paris, France
,
Rafael Sanchez-Salas Department of Urology, Institut Montsouris, 75014 Paris, France
,
Marc Galiano Department of Urology, Institut Montsouris, 75014 Paris, France
,
Eric Barret Department of Urology, Institut Montsouris, 75014 Paris, France
&
Xavier Cathelineau Department of Urology, Institut Montsouris, 75014 Paris, France
Pages 811-818 | Published online: 10 Jan 2014

References

  • D’Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11), 969–974 (1998).
  • Grossfeld GD, Chang JJ, Broering JM et al. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J. Urol. 165(3), 851–856 (2001).
  • Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 95(6), 751–756 (2005).
  • Donohue JF, Bianco FJ Jr, Kuroiwa K et al. Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading. J. Urol. 176(3), 991–995 (2006).
  • Eastham JA, Riedel E, Scardino PT et al.; Polyp Prevention Trial Study Group. Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 289(20), 2695–2700 (2003).
  • Pollack A, Joon DL, Wu CS et al. Quiescence in R3327-G rat prostate tumors after androgen ablation. Cancer Res. 57(12), 2493–2500 (1997).
  • Zietman AL, Nakfoor BM, Prince EA, Gerweck LE. The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study. Cancer J. Sci. Am. 3(1), 31–36 (1997).
  • Zietman AL, Prince EA, Nakfoor BM, Park JJ. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int. J. Radiat. Oncol. Biol. Phys. 38(5), 1067–1070 (1997).
  • Joon DL, Hasegawa M, Sikes C et al. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int. J. Radiat. Oncol. Biol. Phys. 38(5), 1071–1077 (1997).
  • Pollack A, Salem N, Ashoori F et al. Lack of prostate cancer radiosensitization by androgen deprivation. Int. J. Radiat. Oncol. Biol. Phys. 51(4), 1002–1007 (2001).
  • Granfors T, Tomic R, Bergh A, Rydh M, Löfroth PO, Widmark A. After radiotherapy testosterone stimulation is unable to increase growth in the dunning R3327-PAP prostate tumour. Urol. Res. 27(5), 357–361 (1999).
  • Denham JW, Steigler A, Lamb DS et al.; Trans-Tasman Radiation Oncology Group. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 6(11), 841–850 (2005).
  • Pilepich MV, Winter K, Lawton CA et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of Phase III RTOG 85-31. Int. J. Radiat. Oncol. Biol. Phys. 61(5), 1285–1290 (2005).
  • Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a Phase III randomised trial. Lancet 360(9327), 103–106 (2002).
  • Roach M 3rd, Bae K, Speight J et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J. Clin. Oncol. 26(4), 585–591 (2008).
  • Mottet N, Peneau M, Mazeron JJ, Molinie V, Richaud P. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised Phase 3 trial. Eur. Urol. 62(2), 213–219 (2012).
  • Tyrrell CJ, Payne H, See WA et al.; ‘Casodex’ Early Prostate Cancer Trialists Group. Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme. Radiother. Oncol. 76(1), 4–10 (2005).
  • Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K; Casodex Early Prostate Cancer Trialists’ Group. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J. Urol. 172(5 Pt 1), 1865–1870 (2004).
  • Horwitz EM, Bae K, Hanks GE et al. Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: a Phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J. Clin. Oncol. 26(15), 2497–2504 (2008).
  • Bolla M, Van Tienhoven G, De Reijke T. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation for locally advanced prostate cancer: 6 months versus 3 years ADT, results of the randomized EORTC Phase III trial 22961. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 25, Abstract 5014 (2007).
  • Briganti A, Joniau S, Gontero P et al. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. Eur. Urol. 61(3), 584–592 (2012).
  • Hsu C, Joniau S, Van Poppel H. Radical prostatectomy for locally advanced prostate cancer: technical aspects of radical prostatectomy. EAU Update Series 3, 90–97 (2005).
  • Soulié M, Thoulouzan M, Péneau M, Richaud P, Ravery V; les Membres du Sous-Comité Prostate du CCAFU. Surgery of locally advanced prostate cancer. Prog. Urol. 18(13), 1031–1037 (2008).
  • Van Poppel H, Goethuys H, Callewaert P, Vanuytsel L, Van de Voorde W, Baert L. Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer. Eur. Urol. 38(4), 372–379 (2000).
  • Heidenreich A, Ohlmann CH, Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur. Urol. 52(1), 29–37 (2007).
  • Loeb S, Smith ND, Roehl KA, Catalona WJ. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology 69(6), 1170–1175 (2007).
  • Van Poppel H, Vekemans K, Da Pozzo L et al. Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001). Eur. J. Cancer 42(8), 1062–1067 (2006).
  • van den Ouden D, Hop WC, Schröder FH. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J. Urol. 160(4), 1392–1397 (1998).
  • Carver BS, Bianco FJ Jr, Scardino PT, Eastham JA. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. J. Urol. 176(2), 564–568 (2006).
  • Freedland SJ, Partin AW, Humphreys EB, Mangold LA, Walsh PC. Radical prostatectomy for clinical stage T3a disease. Cancer 109(7), 1273–1278 (2007).
  • Johnstone PA, Ward KC, Goodman M, Assikis V, Petros JA. Radical prostatectomy for clinical T4 prostate cancer. Cancer 106(12), 2603–2609 (2006).
  • Boorjian SA, Karnes RJ, Viterbo R et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 117(13), 2883–2891 (2011).
  • Zelefsky MJ, Eastham JA, Cronin AM et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J. Clin. Oncol. 28(9), 1508–1513 (2010).
  • Gomella LG, Zeltser I, Valicenti RK. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer. Urology 62(Suppl. 1), 46–54 (2003).
  • Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur. Urol. 38(6), 706–713 (2000).
  • Scolieri MJ, Altman A, Resnick MI. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated? J. Urol. 164(5), 1465–1472 (2000).
  • Aus G, Abrahamsson PA, Ahlgren G et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int. 90(6), 561–566 (2002).
  • Klotz LH, Goldenberg SL, Jewett MA et al.; Canadian Uro-Oncology Group. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J. Urol. 170(3), 791–794 (2003).
  • Wirth MP, Weissbach L, Marx FJ et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur. Urol. 45(3), 267–270; discussion 270 (2004).
  • Glode L, Tangen C, Hussain M, Wood D, Swanson G. Southwest Oncology Group S9921: prolonged event-free survival in high-risk prostate cancer (PC) patients receiving adjuvant androgen deprivation. J. Clin. Oncol. 27(Suppl. 15), Abstract 5009 (2009).
  • Messing EM, Manola J, Yao J et al.; Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 7(6), 472–479 (2006).
  • Dorff TB, Flaig TW, Tangen CM et al. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J. Clin. Oncol. 29(15), 2040–2045 (2011).
  • Akakura K, Suzuki H, Ichikawa T et al.; Japanese Study Group for Locally Advanced Prostate Cancer. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. Jpn. J. Clin. Oncol. 36(12), 789–793 (2006).
  • Swanson G, Thompson IM, Tangen CM. Update of SWOG 8794: adjuvant radiotherapy for pT3 prostate cancer improves metastasis fee survival. Int. J. Radiat. Oncol. Biol. Phys. 72(S31)(2008).
  • Bolla M, van Poppel H, Collette L et al.; European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366(9485), 572–578 (2005).
  • Wiegel T, Bottke D, Steiner U et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J. Clin. Oncol. 27(18), 2924–2930 (2009).
  • McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP; Casodex Early Prostate Cancer Trialists’ Group. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int. 97(2), 247–254 (2006).
  • Swanson GP, Goldman B, Tangen CM et al.; Southwest Oncology Group 8794. The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794. J. Urol. 180(6), 2453–2457; discussion 2458 (2008).
  • Joniau S, Spahn M. Words of wisdom. Re: adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. Eur. Urol. 60(5), 1121–1122 (2011).
  • Cheville JC, Karnes RJ, Therneau TM et al. Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J. Clin. Oncol. 26(24), 3930–3936 (2008).
  • Spahn M, Kneitz S, Scholz CJ et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int. J. Cancer 127(2), 394–403 (2010).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.